PDF(Pubmed)
Abstract：
UNASSIGNED: Bempedoic Acid (BA) is a novel drug that has a potential to serve as an alternative to statins to decrease lipid levels and improve cardiovascular disease (CVD) outcomes, particularly for statin-intolerant individuals. However, insufficient statistical power has limited our understanding of the efficacy and safety of BA. This meta-analysis utilizes the latest data to improve our knowledge of BA\'s effects on lipids and CVD with increased statistical power.
UNASSIGNED: MEDLINE, Embase, Cochrane Central, Clinicaltrials.gov, abstracts of national and international conferences, and reference lists of studies were searched for relevant studies. Rayyan was used to screen the search results, and Revman 5.3 was used for the meta-analysis and sensitivity analysis.
UNASSIGNED: Our final analysis included seven randomized control trials (RCTs) with 17,782 participants, 53.6 % in the BA group (n = 9535) and 46.4 % in the placebo group (n = 8247). BA significantly decreased major adverse cardiovascular events (MACE) (OR: 0.86; 95 % CI 0.78-0.95; p = 0.03), non-fatal myocardial infarction (OR 0.72; 95 % CI 0.61-0.85; p = 0.0001), and new onset/worsening diabetes (OR:0.55; 95 % CI 0.30-0.98, p = 0.04), while reducing low-density lipoprotein cholesterol (LDL-C) levels by 22.5 % (MD: -22.53 %; 95 % CI -25.54 to -19.52, p < 0.00001).
UNASSIGNED: The findings of this meta-analysis suggest that BA is a promising and effective alternative to statin therapy, particularly for statin-intolerant and high CVD-risk patients. However, further studies with diverse populations are needed to quantify the long-term efficacy and safety endpoints.
UNASSIGNED: MEDLINE, Embase, Cochrane Central, Clinicaltrials.gov, abstracts of national and international conferences, and reference lists of studies were searched for relevant studies. Rayyan was used to screen the search results, and Revman 5.3 was used for the meta-analysis and sensitivity analysis.
UNASSIGNED: Our final analysis included seven randomized control trials (RCTs) with 17,782 participants, 53.6 % in the BA group (n = 9535) and 46.4 % in the placebo group (n = 8247). BA significantly decreased major adverse cardiovascular events (MACE) (OR: 0.86; 95 % CI 0.78-0.95; p = 0.03), non-fatal myocardial infarction (OR 0.72; 95 % CI 0.61-0.85; p = 0.0001), and new onset/worsening diabetes (OR:0.55; 95 % CI 0.30-0.98, p = 0.04), while reducing low-density lipoprotein cholesterol (LDL-C) levels by 22.5 % (MD: -22.53 %; 95 % CI -25.54 to -19.52, p < 0.00001).
UNASSIGNED: The findings of this meta-analysis suggest that BA is a promising and effective alternative to statin therapy, particularly for statin-intolerant and high CVD-risk patients. However, further studies with diverse populations are needed to quantify the long-term efficacy and safety endpoints.
摘要：
■BempedoicAcid（BA）是一种新型药物，有可能作为他汀类药物的替代品，以降低血脂水平并改善心血管疾病（CVD）结局。特别是对于他汀类药物不耐受的个体。然而,统计能力不足限制了我们对BA疗效和安全性的理解.该荟萃分析利用最新数据提高了我们对BA对脂质和CVD的影响的认识，并增加了统计能力。
■MEDLINE,Embase,CochraneCentral,Clinicaltrials.gov,国家和国际会议的摘要，并搜索了相关研究的参考研究清单。Rayyan被用来筛选搜索结果,采用Revman5.3进行Meta分析和敏感性分析。
■我们的最终分析包括7项随机对照试验（RCT），共有17,782名参与者，BA组（n=9535）为53.6%，安慰剂组（n=8247）为46.4%。BA显著降低主要不良心血管事件(MACE)(OR:0.86;95%CI0.78-0.95;p=0.03),非致死性心肌梗死（OR0.72；95%CI0.61-0.85；p=0.0001），和新发/恶化的糖尿病（OR：0.55;95％CI0.30-0.98，p=0.04），同时将低密度脂蛋白胆固醇（LDL-C）水平降低22.5％（MD：-22.53％；95％CI-25.54至-19.52，p<0.00001）。
■这项荟萃分析的结果表明，BA是他汀类药物治疗的一种有希望且有效的替代药物，特别是他汀类药物不耐受和高CVD风险患者。然而,需要对不同人群进行进一步研究,以量化长期疗效和安全性终点.
■MEDLINE,Embase,CochraneCentral,Clinicaltrials.gov,国家和国际会议的摘要，并搜索了相关研究的参考研究清单。Rayyan被用来筛选搜索结果,采用Revman5.3进行Meta分析和敏感性分析。
■我们的最终分析包括7项随机对照试验（RCT），共有17,782名参与者，BA组（n=9535）为53.6%，安慰剂组（n=8247）为46.4%。BA显著降低主要不良心血管事件(MACE)(OR:0.86;95%CI0.78-0.95;p=0.03),非致死性心肌梗死（OR0.72；95%CI0.61-0.85；p=0.0001），和新发/恶化的糖尿病（OR：0.55;95％CI0.30-0.98，p=0.04），同时将低密度脂蛋白胆固醇（LDL-C）水平降低22.5％（MD：-22.53％；95％CI-25.54至-19.52，p<0.00001）。
■这项荟萃分析的结果表明，BA是他汀类药物治疗的一种有希望且有效的替代药物，特别是他汀类药物不耐受和高CVD风险患者。然而,需要对不同人群进行进一步研究,以量化长期疗效和安全性终点.
